Trust Point Inc. Sells 721 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Trust Point Inc. decreased its position in Option Care Health, Inc. (NASDAQ:OPCH) by 5.7% during the 1st quarter, Holdings Channel.com reports. The fund owned 11,982 shares of the company’s stock after selling 721 shares during the quarter. Trust Point Inc.’s holdings in Option Care Health were worth $419,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in OPCH. Wellington Management Group LLP boosted its holdings in Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company’s stock valued at $425,143,000 after acquiring an additional 8,400,208 shares during the last quarter. Norges Bank bought a new position in Option Care Health in the fourth quarter valued at about $60,219,000. Voloridge Investment Management LLC bought a new position in Option Care Health in the fourth quarter valued at about $27,428,000. Freestone Grove Partners LP bought a new position in Option Care Health in the fourth quarter valued at about $17,487,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Option Care Health by 17.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company’s stock valued at $92,518,000 after acquiring an additional 591,042 shares during the last quarter. Institutional investors own 98.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on OPCH shares. JMP Securities reiterated a “market outperform” rating and issued a $36.00 price target on shares of Option Care Health in a report on Tuesday, April 22nd. UBS Group raised Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the company from $38.00 to $40.00 in a research note on Wednesday, April 30th. Barrington Research reissued an “outperform” rating and issued a $38.00 target price on shares of Option Care Health in a research note on Wednesday, April 30th. Finally, JPMorgan Chase & Co. increased their target price on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.50.

Option Care Health Trading Up 0.7%

NASDAQ OPCH opened at $31.82 on Tuesday. The firm has a market cap of $5.21 billion, a P/E ratio of 26.74, a P/E/G ratio of 2.30 and a beta of 0.74. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The stock’s 50-day moving average is $32.20 and its 200-day moving average is $30.41. Option Care Health, Inc. has a one year low of $21.39 and a one year high of $35.53.

Option Care Health (NASDAQ:OPCH) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $1.33 billion for the quarter, compared to analyst estimates of $1.26 billion. Option Care Health had a return on equity of 15.30% and a net margin of 4.37%. Option Care Health’s revenue was up 16.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. Sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.